COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro

Journal of Surgical Research

Volumn 119, Issue 2, 2004, Pages 138-142

  Mohseni, H ^a   Zaslau, S ^a   McFadden, D ^a   Riggs, D R ^a   Jackson, B J ^a   Kandzari, S ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; bladder cancer; COX 1; COX 2; Rofecoxib

Indexed keywords

CATECHIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ROFECOXIB;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

APOPTOSIS; CATECHIN; CELL DIVISION; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; URINARY BLADDER NEOPLASMS;

EID: 2442486078     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.03.005     Document Type: Article

References (13)

1. Sabichi A.L., Lippman S.C. COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog. Exp. Tum. Res. 37:2003;163
2. Serretta V., Pomara G., Piazza F., Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur. Urol. 37:2000;85
3. 2 synthesis in cultured bladder cancer cells. Pathology. 33:2001;469
4. Mosmann T. Rapid colorimetric assay for cellular growth and survival Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55
5. Dixon W.J., Massey F.J. Introduction to Statistical Analysis. 4th ed. 1983;McGraw-Hill, New York
6. Ludbrook J. Multiple comparison procedures updated. Clin. Exp. Pharmacol. Physiol. 25:1998;1032
7. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30:2000;3
8. Howe L.R., Subbaramaiah K., Brown A.M., Dannenberg A.J. Cyclooxygenase-2 A target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer. 8:2001;97
9. Turini M.E., DuBois R.N. Cyclooxygenase-2 A therapeutic target. Annu. Rev. Med. 53:2002;35
10. Leahy K.M., Koki A.T., Masferrer J.L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem. 7:2000;1163
11. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306
12. Rao K.V., Detrisac C.J., Steele V.E., Hawk E.T., Kelloff G.J., McCormick D.L. Differential activity of asprin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 17:1996;1435
13. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., et al. Celecoxib inhibits N-butyl-N(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599